Infrastructure Capital Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Infrastructure Capital Advisors LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,596 shares of the biopharmaceutical company’s stock, valued at approximately $673,000.

Several other institutional investors have also made changes to their positions in HALO. Measured Wealth Private Client Group LLC increased its stake in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the period. Abel Hall LLC grew its holdings in shares of Halozyme Therapeutics by 4.2% during the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 129 shares in the last quarter. StoneX Group Inc. increased its stake in shares of Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after acquiring an additional 132 shares during the last quarter. Twin Capital Management Inc. raised its holdings in shares of Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 161 shares in the last quarter. Finally, Coldstream Capital Management Inc. raised its holdings in shares of Halozyme Therapeutics by 1.9% during the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 165 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

HALO stock opened at $108.17 on Monday. The firm has a market cap of $12.28 billion, a PE ratio of 32.29, a PEG ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $108.49. The company has a fifty day simple moving average of $83.19 and a 200 day simple moving average of $73.74. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period last year, the company earned $1.54 earnings per share. The business’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on HALO shares. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $83.00 to $110.00 in a report on Friday, August 7th. Citizens Jmp boosted their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Finally, TD Cowen increased their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $91.20.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 64,103 shares of company stock valued at $5,226,496. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.